Ep. 376 - M&A momentum: 3Q public markets preview

BioCentury This Week by BioCentury

Jul 13, 202633:01Science & Medicine

M&A enthusiasm is carrying biotech amid tepid reception for launches. On the latest BioCentury This Week podcast, BioCentury’s analysts discuss BioCentury’s 3Q26 Public Markets Preview, asking whether M&A momentum can ca...

Related Episodes

Continue listening to more episodes from BioCentury This Week.

Ep. 385 - MFN deals, Lilly takeout, FDA pick Overton

Aug 31, 2026 - 35:37

Mid-sized biopharma companies are under growing pressure to accept most-favored nation drug pricing deals...

Ep. 384 - Back to School Special: The global FIH trials race

Aug 27, 2026 - 42:31

China has changed the global narrative on delivering early human clinical data, with a new bar for speed...

Ep. 383 - Moderna, Genentech obesity deal, Trump's FDA pick

Aug 24, 2026 - 19:13

A Phase III win for a melanoma vaccine from Moderna and Merck & Co. has opened the door to personalized n...

Ep. 382 - Summer’s venture wave; drugging beta-catenin; Capricor & FDA

Aug 17, 2026 - 25:28

A baker’s dozen of biotechs shrugged off the summer haze to raise nearly $800 million in venture cash. On...

Ep. 381 - FIH urgency in the U.S. Plus: federated learning, biotech IPOs

Aug 10, 2026 - 31:43

Pressure is on FDA, policymakers and academic centers in the U.S. to respond to challenges from China, Au...

Ep. 380 - AZ-BMS rumors, Replimune, psychedelics

Aug 3, 2026 - 32:25

Rumors flew this weekend about a mega-merger of AstraZeneca and Bristol Myers — but would such a deal mak...

Ep. 379 - Argenx M&A, AI giants and biopharma, catalyst scorecard

Jul 27, 2026 - 34:09

Argenx the tier-jumping European biotech, believes its proposed $2.2 billion purchase of Forte Bioscience...

Ep. 378 - U.K. cabinet shuffle, Taiwan biotech and Biogen data

Jul 20, 2026 - 42:07

The departure of U.K. Science Minister Patrick Vallance is a blow for U.K. biotech. On the latest BioCent...